Top 10 Companies in the North America Primary Immunodeficiency Diseases Treatment Market (2026): Market Leaders Powering Global Health

MARKET INSIGHTS

The North America Primary Immunodeficiency Diseases Treatment market was valued at USD 4.52 billion in 2024. The market is projected to grow from USD 4.86 billion in 2025 to USD 7.98 billion by 2032, exhibiting a CAGR of 7.3% during the forecast period.

Primary Immunodeficiency Diseases (PIDs) are a group of more than 450 rare, chronic disorders where part of the body’s immune system is missing or functions improperly. Treatment is primarily aimed at preventing and fighting infections and can include immunoglobulin replacement therapy, which is the cornerstone of treatment for many antibody deficiencies, antibiotic therapies to manage infections, and advanced interventions like stem cell transplantation and gene therapy for curative intent in certain severe conditions.

The market growth is driven by factors such as increasing disease awareness and diagnosis rates, a robust healthcare infrastructure, and high adoption of advanced therapeutics. The rising prevalence of PIDs, estimated to affect between 1 in 1,200 to 2,000 people in the region, underscores the significant patient population. Furthermore, favorable government initiatives and increasing R&D investments by key players for novel therapies, including subcutaneous immunoglobulin (SCIG) products with improved convenience, are propelling the market forward. For instance, in 2024, Takeda Pharmaceutical Company Limited received expanded approvals for its HYQVIA product, reinforcing its position in the market. Leading companies such as Grifols, S.A., CSL Behring, Takeda Pharmaceutical Company Limited, and Octapharma AG dominate the landscape with comprehensive product portfolios.

North America Primary Immunodeficiency Diseases Treatment Market – View in Detailed Research Report

MARKET DRIVERS

Increasing Disease Diagnosis Rates and Awareness

The North America Primary Immunodeficiency Diseases (PID) treatment market is primarily driven by a significant increase in disease diagnosis. Enhanced newborn screening programs, greater awareness among healthcare professionals, and improved diagnostic technologies have led to earlier and more frequent identification of PID cases. This expanding patient pool directly fuels the demand for treatment options, particularly immunoglobulin replacement therapies, which represent the cornerstone of management for many forms of PID.

Advancements in Treatment Modalities

Technological innovation is a powerful driver, with the development of subcutaneous immunoglobulin (SCIG) products offering patients greater convenience and improved quality of life compared to traditional intravenous (IVIG) administration. The market is also witnessing growth in novel therapeutic approaches, including gene therapies and targeted biologics, which promise more precise and potentially curative treatments for specific immunodeficiency disorders.

➤ The market for subcutaneous immunoglobulin is projected to grow at a CAGR of over 8% in North America, reflecting a strong patient preference for home-based care.

Furthermore, robust healthcare infrastructure and favorable reimbursement policies in the United States and Canada ensure patient access to these advanced, albeit high-cost, treatments. The presence of major pharmaceutical companies actively investing in R&D for rare diseases continues to propel the market forward.

MARKET CHALLENGES

High Cost of Therapy and Economic Burden

A primary challenge facing the market is the exorbitant cost associated with lifelong immunoglobulin therapy and other specialized treatments. This places a substantial economic burden on healthcare systems, insurers, and patients, potentially limiting access for some individuals. Managing the logistics and costs of chronic care remains a significant hurdle for both providers and payers.

Other Challenges

Diagnostic Delays and Misdiagnosis
Despite improvements, many PID cases still experience diagnostic delays, sometimes for years, as symptoms can be non-specific and overlap with more common conditions. This delay in definitive diagnosis postpones critical treatment initiation, impacting patient outcomes.

Treatment-Related Complications
Patients on long-term therapy, especially IVIG, face risks of adverse reactions, including headaches, infusion-related reactions, and, in rare cases, thrombotic events. Managing these complications requires careful monitoring and adds complexity to patient care.

MARKET RESTRAINTS

Stringent Regulatory Hurdles for Novel Therapies

The development and approval of new therapies for rare diseases like PID are subject to rigorous regulatory scrutiny by agencies such as the FDA and Health Canada. The complex nature of these diseases, coupled with small patient populations for clinical trials, makes it challenging to generate the robust data required for market authorization. This stringent process can slow down the introduction of innovative treatments.

Limited Patient Pool and Market Size

While diagnosis is improving, PID remains a collection of rare disorders. The inherently small patient population limits the commercial incentive for extensive investment compared to more prevalent diseases. This can restrain the pace of broad-based research and the number of companies actively pursuing new PID treatments.

MARKET OPPORTUNITIES

Expansion of Personalized and Curative Therapies

The most significant opportunity lies in the development of personalized medicine, including gene therapy and hematopoietic stem cell transplantation (HSCT). Advances in genetic engineering, such as CRISPR, hold the potential to provide curative solutions for monogenic forms of PID, moving beyond lifelong symptomatic management. This represents a paradigm shift in treatment.

Growth in Home-Based Care and Digital Health

The trend towards self-administration of SCIG at home creates opportunities for companies to develop integrated support systems, including training programs, remote monitoring devices, and digital platforms for patient management. This not only improves patient convenience but also opens new service-oriented revenue streams.

Furthermore, there is substantial opportunity in emerging markets within North America, particularly in improving diagnosis and access to care in underserved rural and remote communities. Initiatives focused on physician education and telehealth can help bridge this gap and unlock new patient segments.

---

🔟 1. Takeda Pharmaceutical Company Limited

Headquarters: Tokyo, Japan (Global HQ with major N.A. operations)
Key Offering: HYQVIA (SCIG), other immunoglobulin products

Takeda has cemented its position as a leader in immunology with a robust pipeline of SCIG products. The expanded approval of HYQVIA in 2024 has broadened its therapeutic reach across antibody deficiencies.

Sustainability & Growth Initiatives: Commitment to reducing carbon footprint through greener manufacturing, investment in digital health platforms for patient monitoring.

• Expansion of SCIG portfolio to include high-concentration formulations.
• Strategic collaborations with regional distributors to enhance market penetration.
• Investment in AI-driven diagnostics to accelerate PID identification.

9️⃣ 2. CSL Behring

Headquarters: King City, Canada
Key Offering: IVIG & SCIG products, plasma-derived therapies

CSL Behring remains a cornerstone in the immunoglobulin market, providing high-quality products that support patients worldwide.

Sustainability & Growth Initiatives: Focus on circular economy through plasma collection and recycling.

• Launch of next-generation recombinant Ig products.
• Partnerships with diagnostic labs for early PID detection.
• Investment in patient support programs for home infusion.

8️⃣ 3. Grifols, S.A.

Headquarters: Barcelona, Spain (Major N.A. presence)
Key Offering: Immunoglobulin products, plasma fractionation technology

Grifols leverages its plasma fractionation expertise to deliver high-quality immunoglobulin therapies across North America.

Sustainability & Growth Initiatives: Commitment to sustainable plasma collection and waste reduction.

• Expansion of SCIG manufacturing capacity.
• Strategic alliances with U.S. hospitals for patient education.
• Development of digital adherence tools.

7️⃣ 4. Octapharma AG

Headquarters: Swindon, United Kingdom (Major N.A. presence)
Key Offering: Immunoglobulin products, plasma-derived therapies

Octapharma’s focus on personalized immunoglobulin solutions positions it as a key player in the PID market.

Sustainability & Growth Initiatives: Investment in renewable energy for manufacturing facilities.

• Development of subcutaneous formulations.
• Collaboration with specialty clinics for patient support.
• Digital health platform for remote monitoring.

6️⃣ 5. Biomarin Pharmaceutical Inc.

Headquarters: North Carolina, USA
Key Offering: Immunoglobulin products, specialty therapies

Biomarin continues to expand its portfolio with innovative immunoglobulin solutions tailored for PID patients.

Sustainability & Growth Initiatives: Focus on reducing water usage in manufacturing.

• Launch of SCIG product lines.
• Strategic partnerships with academic centers.
• Investment in patient education programs.

5️⃣ 6. Sanofi

Headquarters: Paris, France (Global HQ with major N.A. operations)
Key Offering: Immunoglobulin products, rare disease therapies

Sanofi’s comprehensive portfolio and strong R&D pipeline support its leadership in the PID market.

Sustainability & Growth Initiatives: Commitment to 100% renewable energy for all facilities by 2030.

• Expansion of gene therapy pipeline.
• Collaboration with biotech startups.
• Investment in digital health solutions.

4️⃣ 7. Mustang Bio, Inc.

Headquarters: South San Francisco, California, USA
Key Offering: Gene therapies for PID

Mustang Bio is at the forefront of gene therapy development, offering curative solutions for monogenic PID disorders.

Sustainability & Growth Initiatives: Focus on scalable manufacturing processes.

• Clinical trials for ADA-SCID gene therapy.
• Partnerships with global biotechs.
• Investment in CRISPR-based platforms.

3️⃣ 8. Orchard Therapeutics

Headquarters: Cambridge, United Kingdom (N.A. clinical operations)
Key Offering: Gene therapies for PID

Orchard Therapeutics specializes in lentiviral vector-based gene therapies for rare immune disorders.

Sustainability & Growth Initiatives: Commitment to responsible manufacturing.

• Development of XLA gene therapy.
• Strategic alliances with research institutions.
• Digital patient support platform.

2️⃣ 9. Rocket Pharmaceuticals, Inc.

Headquarters: New York, New York, USA
Key Offering: Immunoglobulin products, specialty therapies

Rocket Pharmaceuticals focuses on delivering high-quality immunoglobulin therapies with a strong emphasis on patient care.

Sustainability & Growth Initiatives: Investment in green manufacturing.

• Expansion of SCIG line.
• Partnerships with homecare providers.
• Digital adherence tools.

1️⃣ 10. ADMA Biologics, Inc.

Headquarters: South San Francisco, California, USA
Key Offering: Gene therapies, rare disease solutions

ADMA Biologics is developing innovative gene therapies for PID and other rare disorders.

Sustainability & Growth Initiatives: Focus on scalable manufacturing and patient access.

• Clinical trials for gene therapy for XLA.
• Strategic collaborations with biotech firms.
• Investment in digital health platforms.

---

Download FREE Sample Report:
Download FREE Sample Report

Get Full Report:
Get Full Report

---

OUTLOOK

The North America Primary Immunodeficiency Diseases Treatment market is poised for sustained growth, driven by increasing disease awareness, robust healthcare infrastructure, and a surge in advanced therapeutics. The shift towards subcutaneous immunoglobulin (SCIG) therapies is expected to accelerate, offering patients greater convenience and reducing reliance on clinical infusion centers. Gene therapy and stem cell transplantation are emerging as curative options, potentially transforming the treatment paradigm for severe PID cases.

FUTURE TRENDS

• Personalized Medicine: Expansion of gene editing technologies (CRISPR, base editing) to correct underlying genetic defects.
• Home-Based Care: Integration of digital health platforms for remote monitoring and patient support.
• Strategic Consolidation: M&A activity among biopharmaceuticals and biotech firms to acquire promising pipelines and expand market reach.
• Regulatory Harmonization: Efforts to streamline approvals across U.S. and Canada, reducing time to market.
• Access Expansion: Telehealth initiatives to reach underserved rural communities, enhancing early diagnosis and treatment.